• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    C

    Coloplast Inc.

    企业
    79论文总数
    1,173引用总数

    Coloplast A/S is a Danish multinational company that develops, manufactures and markets medical devices and services related to ostomy, urology, continence, and wound care..

    论文量&引用量时间轴

    机构学者

    论文(79)

    年份
    起
    –
    止
    排序
    1Length of Stay in Acute Burn Patients Treated with Intact Fish Skin Graft Versus Synthetic Skin Substitutes
    Rajiv Sood, Nathanael D Hevelone, Olafur B Davidsson, Ragnar P Kristjansson,Bart D Phillips,John C Lantis, Gunnar Johannsson

    Objective: To compare hospital length of stay (LOS) and complication rates between patients treated with intact fish skin graft (IFSG; Kerecis) and synthetic/biosynthetic dermal substitutes (SSS; Integra and NovoSorb BTM) prior to autograft using the ABA Burn Care Quality Platform. Methods: Adult acute-burn patients treated with either IFSG or SSS were identified from the American Burn Association Burn Care Quality Platform. IFSG patients were 1:4 propensity matched to SSS patients on age, sex, TBSA, burn severity, inhalation injury, and trauma. Primary outcome was hospital length of stay (Gamma GLMM); composite secondary was sepsis, graft loss, VTE, or HAPI (binomial GLMM). Results: 93 IFSG and 372 SSS patients across 49 burn centers were analyzed with acute burns represented as moderate sized (mean TBSA 12.6%), with burn depth predominantly mixed or third degree. GLMM adjusted mean length of stay was 22.7 days (95% CI 18.2 to 28.3) for IFSG versus 35.2 days (95% CI 30.9 to 40.1) for SSS (ratio 0.646; p = 0.000235), a 12.4 day reduction. The composite complication rate was 7.5% (7/93) in IFSG versus 15.9% (59/372) in SSS (GLMM odds ratio 2.37, 95% CI 1.03 to 5.42; p = 0.041). All individual complications were numerically lower in the IFSG arm. Conclusions: In this propensity matched analysis of the ABA registry, IFSG was associated with a statistically significant 12.4 day reduction in length of stay and a significantly lower composite complication rate. IFSG is an effective alternative for burns requiring dermal substitution and autografting. Prospective studies in larger burns are warranted. ### Competing Interest Statement This study was funded by Kerecis, LLC. RS and JCL have served as consultants to Kerecis. JCL is the Chairman of the Kerecis Scientific Advisory Board and the Director of their Clinical trials council; for which Little Black Raincloud Inc receives fair market compensation, JCL is a Co-Director of Little Black Raincloud Inc. NDH and BDP are employees of BData Inc., which received funding from Kerecis to perform the data extraction and propensity-matching analyses. OBD and RPK are employees of Frameshift ApS, which received funding from Kerecis to perform the independent statistical analyses. BData and Frameshift performed all analyses independently. The sponsor had no access to patient-level data at any point during the study. GJ is an employee of Kerecis (Coloplast), the manufacturer of the intact fish skin graft (GraftGuide) evaluated in this study. ### Funding Statement This study was funded by Kerecis, LLC. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: WCG IRB Connexus gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data in this study is generally unavailable with possible exceptions. Kerecis, LLC

    2026
    引用
    AI阅读
    加入学术空间
    2Prise En Charge Des Troubles Urinaires Dans La Sclérose En Plaques : Analyse Nationale En Vie Réelle À Partir Des Données Du SNDS
    Cécile Donzé,Emmanuelle Leray, Emmanuel Chartier-Kastler, Souad Meillassoux, Camille Roussillon, Julien Gautry,Sandra Vukusic

    Introduction Les troubles urinaires sont fréquents dans la sclérose en plaques (SEP), altèrent la qualité de vie et augmentent le risque de complications en cas de prise en charge insuffisante. Objectifs Décrire, à l’échelle nationale, la prise en charge des troubles urinaires chez les personnes atteintes de SEP à partir des données du Système National des Données de Santé. Méthodes Étude rétrospective incluant les patients SEP identifiés dans le SNDS entre 2005 et 2020 selon le statut ALD, les hospitalisations (G35) ou les traitements de fond. La prise en charge urinaire incluait examens urinaires, traitements pharmacologiques, dispositifs médicaux, interventions invasives et chirurgie urologique. Deux périodes ont été analysées : période historique 2013–2020 et période de suivi 2021–2022. Les patients étaient classés en cinq niveaux de prise en charge. Résultats Au total, 127 987 patients SEP ont été inclus. Une évaluation urinaire a concerné 26,6 % des patients, incluant 24,2 % d’échographies et 7,9 % de bilans urodynamiques. 8,9 % des patients ont été hospitalisés pour motif urinaires. Un traitement a été délivré chez 29,8 % : non invasif 26,7 %, invasif 10,2 % et chirurgical 1,4 %. Parmi les patients avec une ancienneté d’ALD de 0 à 5 ans, 20,3 % ont été traités. Discussion La faible proportion de patients explorés et traités suggère un sous-dépistage persistant des troubles urinaires, un accès limité aux consultations spécialisées de neuro-urologie, une possible fatigue thérapeutique, ainsi qu’une coordination interdisciplinaire insuffisante entre neurologues, spécialistes en MPR et urologues dans le suivi longitudinal des patients atteints de SEP. Conclusion Les troubles urinaires dans la SEP restent sous-diagnostiqués et sous-traités en France, avec une prise en charge majoritairement non invasive, en décalage avec les recommandations de prise en charge graduée.

    2026Revue Neurologique(2026)
    引用
    AI阅读
    加入学术空间
    3Cost-effectiveness Analysis of Third-Generation Heat and Moisture Exchangers in Patients Who Underwent Laryngectomy in Japan
    Nobuhiko Oridate, Thea Smedby, Chiara Ruzza, Michaela Roth, Mansi Mehta, Yoko Akachi, Rasmus Skovgaard, Takatoshi Itagaki

    National health insurance coverage for third-generation heat and moisture exchanger (HME) was approved in Japan for patients after total laryngectomy (TL). Our study evaluated the cost-effectiveness of third-generation HMEs (Provox® Life™ such as Provox® Life Night, Go, Home, Energy, and Protect) versus second-generation HMEs and no HME for patients who underwent TL in Japan. A Markov model with five health states was developed using an existing model from a Japanese public healthcare payer perspective, with a time horizon of 10 years and a cycle length of one year. Primary outcome was incremental cost-effectiveness ratio (ICERs), while secondary outcomes were pulmonary infection, mucus plug event and skin irritation. One-way sensitivity analyses (OWSA) and Probabilistic Sensitivity Analysis (PSA) were also conducted to determine the robustness of model conclusions. Third-generation HMEs resulted in an ICER of JPY 2,350,010 per QALY gained, at a willingness-to-pay threshold of JPY 5,000,000 per QALY gained, as compared to second-generation HMEs, indicating cost-effectiveness. Similarly, with an ICER of JPY 4,708,917 per QALY gained, third-generation HMEs were also more cost-effective than no HME. Third-generation HMEs showed a decrease in pulmonary infections (average amounts of pulmonary infections per patient over 10 years: 0.26 vs. 0.39 and 0.55), mucus plug event (0.29 vs. 0.47 and 2.14) and skin irritation (1.80 vs. 2.78 and 0.00) compared to second-generation HMEs and no HME. According to OWSA, the transition probabilities between health states were the main drivers for the cost difference between third-generation and second-generation HMEs. PSA confirmed the robustness of the findings. This is the first study to evaluate cost-effectiveness of HMEs in Japan, suggesting that third-generation HMEs (Provox® Life™) are more cost-effective compared to second-generation HMEs and no HME for patients who underwent TL in Japan.

    2025Cost Effectiveness and Resource Allocation(2025)
    引用
    AI阅读
    加入学术空间
    4Cost-Effectiveness of a Digital Leakage Notification System (heylo™) for People with Ileostomies or Colostomies in the United Kingdom
    Esben Bo Boisen, Matthew Cawson, Lasse de Fries Jensen, Stuart Mealing, Naomi van Hest

    People with stomas report a substantial negative impact of stomal effluent leaking outside the ostomy baseplate and subsequent complications in their professional and social lives, causing immense worry. However, many patients are not able to recognize leakages in a timely manner. We conducted a cost-effectiveness study to evaluate the impact of a digital leakage notification system (DLNS) to reduce leakages outside the baseplate (LOB) and worry about leakage for people with intestinal stomas from a UK National Health Service and Personal Social Services perspective. A Markov model for ostomy care was used to compare health-related quality of life and costs for adults with ileostomies or colostomies using UK standard of care ostomy products with the DLNS (intervention) or without the DLNS (comparator). The base case model used a 3-year time horizon with 1-week cycles and an annual 3.5

    2025PharmacoEconomics(2025)
    引用
    AI阅读
    加入学术空间
    5MS Bladder Check Tool: Development and Validation of a Patient Awareness Tool to Facilitate Timely Management of Lower Urinary Tract Dysfunction Due to Multiple Sclerosis
    Giampaolo Brichetto,Peter Flachenecker,Bertil Blok,Jalesh Panicker,Veronique Phe,Kim Barken

    BACKGROUND:Lower urinary tract dysfunction impacts quality of life of people with MS; often, symptoms are 'lived with' or deprioritised by healthcare providers (HCPs). Consequently, patients must be given the skills they need to become confident in managing their illness and enhance their involvement in the process.OBJECTIVE:To develop and validate a self-assessment tool to help people with MS become more aware of their bladder symptoms and prompt contact with their HCP to facilitate timely management and specialist referral, if required.METHODS:The 'MS bladder check tool' was developed by a multidisciplinary panel of specialist advisors. Consensus meetings and pilot testing were conducted to design and evolve the tool into a series of nine questions, using population-appropriate language, and covering all aspects of bladder dysfunction in MS. The tool was then validated by an international, multidisciplinary team of experts.RESULTS:Validity was rated 'excellent' for all questions indicating that the MS bladder check tool is an appropriate method of highlighting bladder problems in people with MS.CONCLUSION:The MS bladder check tool is simple, easy-to-use, and empowers patients to take charge of their urinary tract health, aiming to improve the management of MS and, ultimately, patient quality of life.

    2024MULTIPLE SCLEROSIS JOURNAL(2024)引用:6
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 79 篇论文

    合作机构(78)

    杜克大学合作论文 4
    Beaumont Health合作论文 3
    哥本哈根大学合作论文 3
    加州大学旧金山分校合作论文 3
    加利福尼亚大学戴维斯分校合作论文 3
    匹兹堡大学合作论文 3
    Bispebjerg Hospital合作论文 3
    不列颠哥伦比亚大学合作论文 3
    哥本哈根大学医院合作论文 3
    普利兹克医学院合作论文 2

    机构统计